Targets and outcomes of psychotherapies for mental disorders:an overview by Cuijpers, Pim
VU Research Portal





DOI (link to publisher)
10.1002/wps.20661
document version
Publisher's PDF, also known as Version of record
document license
Article 25fa Dutch Copyright Act
Link to publication in VU Research Portal
citation for published version (APA)
Cuijpers, P. (2019). Targets and outcomes of psychotherapies for mental disorders: an overview. World
Psychiatry, 18(3), 276-285. https://doi.org/10.1002/wps.20661
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
E-mail address:
vuresearchportal.ub@vu.nl
Download date: 27. May. 2021
276 World Psychiatry 18:3 - October 2019
FORUM – TARGETS AND OUTCOMES OF PSYCHOTHERAPIES FOR MENTAL DISORDERS
Targets and outcomes of psychotherapies for mental disorders: 
an overview
Pim Cuijpers
Department of Clinical, Neuro and Developmental Psychology, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
It is not yet clear what mental disorders are and what are the causal pathways that lead to them. That makes it difficult to decide what the tar­
gets and outcomes of psychotherapies should be. In this paper, the main types of targets and outcomes of psychotherapies are described, and a brief 
overview is provided of some of the main results of research on these types. These include symptom reduction, personal targets and outcomes 
from the patient’s perspective, improvement of quality of life, intermediate outcomes depending on the theoretical framework of the therapist, 
negative outcomes to be avoided, and economic outcomes. In line with the dominance of the DSM and ICD systems for diagnoses, most research 
has been focused on symptom reduction. This considerable body of research, with hundreds of randomized trials, has shown that for most mental 
disorders effective psychotherapies are available. There is also research showing that psychotherapies can result in improvement of quality of life 
in most mental disorders. However, relatively little research is available on patient­defined outcomes, intermediate outcomes, negative outcomes 
and economic outcomes. Patients, relatives, therapists, employers, health care providers and society at large each have their own perspectives on 
targets and outcomes of psychotherapies. The perspective of patients should have more priority in research, and a stan dardization of outcome 
measures across trials is much needed.
Key words: Psychotherapies, outcomes, targets, symptom reduction, quality of life, patient-defined outcomes, intermediate outcomes, cog-
nitive behavior therapy
(World Psychiatry 2019;18:276–285)
Mental disorders are one of the most im-
portant public health challenges of this 
time1,2. With hundreds of millions people 
worldwide affected by them, these disor-
ders are associated with severe personal 
suffering by patients and their relatives, 
considerable transgenerational transmis-
sion3-5, huge economic costs6, and in-
creased levels of physical morbidity and 
mortality7,8.
It is, however, still not clear what these 
disorders exactly are. There are no ob-
jective tests or measures to establish the 
presence of a mental disorder, nor are 
there clear thresholds for when a patient 
has a disorder and when not. The domi-
nant systems for classifying and defin-
ing mental disorders in the past decades 
have been the Diagnostic and Statistical 
Manual of Mental Disorders (DSM) and 
the International Classification of Dis-
eases (ICD). Although most research on 
mental disorders in the past decades has 
been using the different versions of these 
systems, they have been widely criticized.
For example, there is evidence that 
most mental disorders should not be con-
sidered as separate entities but rather 
as consisting of dimensions, on which 
some people score high and others score 
low9-11. Furthermore, high levels of co-
morbidity are more the rule than the ex-
ception12. Some argue that the diagnostic 
categories in the DSM and ICD have lim-
ited validity13. Treatments are also typi-
cally not effective in just one disorder, but 
across several different disorders, such as 
pharmacotherapies in mood and anxiety 
disorders, and cognitive behavior therapy 
(CBT) in most mental disorders12.
So, if we do not yet really know what 
these disorders are and how they should 
be defined, what should be the targets of 
treatments and how can we measure their 
outcomes? The overall goal of treatments 
obviously is to make patients better or to 
help them cope with the problems they 
have. What this exactly means, however, 
and when it can be considered as accom-
plished, is not so clear. Not only because 
the nature and causes of the disorders are 
unclear, but also because it depends on 
whether one asks the patient, the clini-
cian, patient’s relatives, health insurance 
companies, or society at large to answer 
this question.
The focus of this paper is on the tar-
gets and outcomes of psychotherapies. 
We define the targets of a therapy as what 
should be tried to accomplish during the 
process. Outcomes are the results of a 
therapy. Because targets and outcomes 
are very much intertwined, we will con-
sider them together in the discussion be-
low, and often use the term “outcome” 
while we mean the broader concept that 
also includes targets.
We distinguish different types of out-
comes: symptom reduction, which is the 
focus of most outcome research in psy-
chotherapy; patient-defined outcomes; 
quality of life improvement; intermediate 
outcomes based on the theoretical frame-
work and assumptions of the therapist; 
negative outcomes to be avoided; and eco-
nomic outcomes. A summary of the types 
of outcomes, the research available on 
these outcomes, the results obtained, and 
the overall status of research is present-
ed in Table 1.
SYMPTOM REDUCTION 
AS OUTCOME OF 
PSYCHOTHERAPIES
Symptom reduction can be seen as the 
core target and outcome of psychothera-
pies. Not only is symptom reduction by far 
the most common focus of outcome re-
search, especially randomized trials, but 
qualitative studies also show that it is one 
of the most important outcomes from the 
viewpoint of patients (although certainly 
not the only one)14. Apart from research-
ers and patients, symptom reduction is 
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also a core outcome for other stakehold-
ers, including therapists, although this de-
pends on the model they adhere to.
The hundreds of randomized trials that 
have examined the effects of psychother-
apies for mental disorders have mostly 
focused on symptom reduction as the pri-
mary outcome. In Table 2, the results are 
presented of some recent meta-analyses 
of psychotherapies (mostly CBT) com-
pared to control conditions for the most 
important mental disorders. For each dis-
order, three of the largest meta-analyses 
published in the past five years are pre-
sented, and the type of intervention, the 
format of the intervention (individual, 
group, guided or unguided self-help), and 
the type of control group are summarized. 
We also report the number of studies in-
cluded in each meta-analysis, the effect 
size (standardized mean difference), the 
level of heterogeneity in percentages (I2), 
and whether it was a conventional or a 
network meta-analysis.
The effect sizes for depression, anxiety 
disorders (social anxiety disorder, panic 
disorder, generalized anxiety disorder), 
post-traumatic stress disorder and obses-
sive-compulsive disorder are moderate 
to large, with most effect sizes between 
0.5 and 1.5. Effect sizes for psychotic and 
bipolar disorders are somewhat smaller, 
but that may also be related to the fact 
that control conditions typically consist 
of care-as-usual, which in these disor-
ders means that most patients received 
intensive pharmacological treatment.
These findings clearly support the as-
sumption that (at least some) psycho-
therapies have significant effects on most 
mental disorders when reduction of symp-
toms is taken as the primary outcome. 
However, these findings have been criti-
cized as being too optimistic, because of 
publication bias33-35, low quality and valid-
ity of many trials15,36, and problems such 
as “researcher allegiance”37, i.e. “the belief 
in superiority of an intervention and the 
superior validity of the theory of change 
that is associated with the treatment”38. 
Most research was also aimed at the short 
term, and longer-term effects are largely 
unknown. Furthermore, there are indica-
tions that one type of control condition, i.e. 
waiting list, may overestimate the effect of 
a therapy39,40.
One major problem in examining the 
effects of psychotherapies on symptoms 
is that the instruments measuring change 
vary widely. For example, we identified 
Table 1 Summary of  the main targets and outcomes of  psychotherapies for mental disorders
Type of target and outcome Research Results Status of research
Symptom reduction Examined in hundreds of  
 randomized trials for many 
types of  psychotherapy for all 
major mental disorders
Effective therapies exist for most mental disorders 
in the short term
Effects are probably overestimated because of  
publication bias, low trial quality, lack of  
blinding
Wide variety in measures
Most research on the effects of  
psychotherapy is focused on 
symptom reduction
Patient-defined targets  
and outcomes
Idiographic measures of  the main 
problems as experienced by 
patients, such as the Target 
 Complaints, the Simplified 
 Personal Questionnaire, and the 
Youth Top Problems
These measures are mostly used in routine care Limited systematic research 
available
Qualitative research on the 
 personal targets and outcomes 
of   psychotherapies
Helpful impact of  therapies: awareness, insight, 
self-understanding, behavioral change, 
 solution of  problems, empowerment, relief, 
better understanding of  feelings
Limited systematic research 
available
Quality of life and related  
targets and outcomes
Studied as a (secondary) outcome in 
randomized trials
Significant effects of  therapies on quality of  
life have been found for depression,  eating 
disorders and anxiety disorders, but not 
 schizophrenia
Relatively well-studied, but 
more research is clearly 
needed
Intermediate outcomes: 
mediators and working 
mechanisms
Each school of  psychotherapy has 
its own theoretical framework to 
explain how therapy works
Mediators and working mechanisms have not 
been well established for any therapy, because 
of  methodological problems
Limited systematic research 
available
Negative outcomes Have become the focus of  research 
only recently
Preliminary research suggests that deterioration 
in psychotherapies is lower than in control 
conditions
Several types of  negative effects have not been 
examined systematically
Individual patient data meta-analyses are 
a  promising approach
Limited systematic research 
available
Economic outcomes Studies include cost-utility and 
 cost-effectiveness analyses
For most mental disorders no more than one or 
two studies of  psychotherapies are available
Some more studies are available for cognitive 
behavior therapy in depression
Limited systematic research 
available
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Table 2 Meta-analyses of  randomized trials examining the effects of  psychotherapies compared to control conditions
Intervention Format Comparator N studies SMD 95% CI I2 Type
Depression
Cuijpers et al15 Any therapy Individual/group/
guided self-help
Any control 369 0.70 0.64-0.75 76 CMA
Mohr et al16 Any therapy Individual/group/
guided self-help
Any control 188 0.54 0.45-0.64 82 CMA
Cuijpers et al17 CBT Individual/group/
guided self-help
Any control 94 0.71 0.62-0.79 57 CMA
Social anxiety disorder




48 0.88 0.74-1.03 64 CMA
Mayo-Wilson et al19 CBT Group Waiting list 28 0.92 0.51-1.33 NA NMA
Barkowski et al20 CBT Group Waiting list 25 0.84 0.72-0.97 0 CMA
Panic disorder




42 0.81 0.59-1.04 77 CMA
Pompoli et al21 CBT Individual/group Waiting list 17 1.14 0.87-1.41 61 NMA
Mayo-Wilson &  Montgomery22 CBT Guided/unguided  
self-help
No treatment 21 0.62 0.45-0.79 23 CMA
Generalized anxiety disorder
Cuijpers et al23 Any therapy Individual/group/
guided self-help
Any inactive control 38 0.84 0.71-0.97 33 CMA




31 0.80 0.67-0.93 33 CMA
Mayo-Wilson &  Montgomery22 CBT Guided/unguided  
self-help
No treatment 10 0.95 0.44-1.45 88 CMA
Post-traumatic stress disorder
Bisson et al24 TF-CBT/Exposure Individual Waiting list, care-as-usual 28 1.62 1.21-2.03 89 CMA
Bisson et al24 TF-CBT/Exposure Group Waiting list, care-as-usual 16 1.20 0.69-1.70 71 CMA
Gerger et al25 CBT Individual Waiting list 16 1.10 0.85-1.36 NA NMA
Obsessive-compulsive disorder
Olatunji et al26 CBT Individual/group Waiting list, pill or 
 psychological placebo
16 1.39 1.04-1.74 NA CMA
Ost et al27 CBT Individual/group Waiting list 15 1.31 1.08-1.55 37 CMA
Ost et al27 CBT Individual/group Pill or psychological 
placebo
8 1.33 0.91-1.76 72 CMA
Psychotic disorders
Velthorst et al28 CBT Individual/group Any control 28 0.09 –0.03 to 0.21 63 CMA
Burns et al29 CBT Individual Any control 12 0.52 0.35-0.70 0 CMA
Eichner & Berna30 Metacognitive 
training
Individual/group Any control 11 0.34 0.15-0.53 3 CMA
Bipolar disorder
Chatterton et al31 Psychoeducation 
+ CBT
Individual/group Care-as-usual 16 0.58 –1.25 to 2.41 NA NMA
Chatterton et al31 Psychoeducation Individual/group Care-as-usual 12 0.14 –1.01 to 1.30 NA NMA
Chiang et al32 CBT Individual/group Any control 13 0.49 0.03-0.96 90 CMA
CBT – cognitive behavior therapy, TF – trauma focused, SMD – standardized mean difference, CMA – conventional meta-analysis, NMA – network meta-analysis, 
NA – not available
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310 randomized trials comparing psy-
chotherapies with a control condition in 
people with depression15. Although the 
Beck Depression Inventory (BDI)41 and 
the Hamilton Rating Scale for Depres-
sion (HAMD)42 were the most used in-
struments, there were more than thirty 
other instruments measuring the impact 
of psychotherapies on depressive symp-
toms. As a comparison, in a recent meta-
analysis of more than 500 randomized 
trials of pharmacotherapy for depression, 
89% used the HAMD as the primary out-
come measure43.
Actually, the variety of instruments 
measuring an outcome was one of the 
main reasons why meta-analyses were 
introduced44. In a meta-analysis, the ef-
fect measured with one instrument is 
standardized into an “effect size”, in or-
der to pool it with the effects using other 
instruments. If all studies used the same 
outcome measure, this standardization 
would not be needed, because it would 
be possible to simply calculate the benefit 
of an intervention in terms of exact points 
on that measure.
Another issue is whether symptoms 
should be measured through self-report 
or clinician-rated instruments. It could 
be assumed that clinician-rated instru-
ments provide a better estimate of the 
effects of an intervention, because they 
are applied by an independent observer 
(especially if the interviewer is blinded to 
the treatment condition). On the other 
hand, symptoms are experienced by pa-
tients, so one can also argue that patients 
themselves are the best raters of their 
problems. Furthermore, there are indica-
tions that outcomes rated by patients are 
more conservative than those rated by 
clinicians. We found in a meta-analysis 
that effect sizes of self-report measures 
were significantly smaller than clinician-
rated measures from the same studies (dif-
ferential effect size of g=0.20)45.
There is no consensus about whether 
or not reduction of symptoms should be 
considered as the core outcome of psy-
chotherapies. Therapists and researchers 
from the cognitive and behavioral tradi-
tion do support the notion that symptom 
change is the core outcome. However, 
therapists from the psychodynamic tra-
dition consider personality and intrapsy-
chic change as much more important46, 
even if it cannot be measured very well. 
For them, symptoms are only the result of 
these personality and intrapsychic prob-
lems. They are assumed not to be the 
real core problem, and to improve when 
the personality and intrapsychic change 
is obtained. Therapists from the client-
centered tradition would argue that self- 
actualization is the core outcome of ther-
apy, and that symptoms are only one of 
the triggers for patients to find help.
In some cases, a worsening of symp-
toms can even be considered a positive 
outcome of therapy46. For example, it has 
been argued that the emergence of de-
pression during existential psychotherapy 
could be a sign that the patient is being 
more in touch with reality, which in turn 
motivates urgency to reevaluate priori-
ties47.
The strong focus in research on the re-
duction of symptoms is in part related to 
the wide acceptance of the DSM and ICD, 
which have been dominating the field 
of mental health research in the past 50 
years48. In recent years, however, the cri-
tique of these systems is strongly increas-
ing. According to several authors12,15,49, 
the progress in improving outcomes of 
treatments of mental disorders is not be-
ing satisfactory, and, in order to change 
that, new systems to understand mental 
disorders are needed.
One of the most important new pro-
jects that challenge the dominance of 
the DSM and ICD is the Research Do-
main Criteria (RDoC) initiative, launched 
by the US National Institute of Mental 
Health50,51. The RDoC is not based on the 
clinical descriptions of disorders, but con-
siders these disorders from a translational 
point of view12. It starts with the funda-
mental, primary behavioral functions of 
the brain and the neural systems that are 
involved in the implementation of these 
functions. Examples are the circuits for 
fear and defense, for appetitive behavior 
such as learning to predict reward and 
moving toward reward, and for cognitive 
functions such as working memory12. 
The RDoC considers psychopathology as 
dysfunction in these systems. At this mo-
ment, it is too early to say whether this 
new approach will indeed result in new 
knowledge about if and how therapies 
work.
PATIENT-DEFINED TARGETS 
AND OUTCOMES OF 
PSYCHOTHERAPIES
A completely different type of targets 
and outcomes of psychotherapies are 
those that are defined by patients them-
selves. Patients typically do not only come 
to therapy to obtain relief from symp-
toms, but also to address other personal 
problems, which may include going back 
to work, solving intrapersonal issues, be-
ing a better parent, or stopping the fights 
with their partner or their boss. Address-
ing these problems of the patient can be 
regarded as one of the main goals of ther-
apy52,53.
Although these individual problems 
have not been examined as extensively as 
symptom reduction, there is a long tradi-
tion of research focusing on them, going 
back to the 1960s54. Several standardized 
measures have been developed to exam-
ine the targets and outcomes that are rel-
evant from the perspective of the patient. 
In this context, the difference between 
nomothetic and idiographic outcome 
measures is relevant. Most outcome mea-
sures are nomothetic, which means that 
items of the measure are common to all 
people in varying degrees, and the mea-
sure is aimed at locating where a patient 
scores on that dimension55. Idiographic 
measures, on the other hand, rely on the 
unique features and views of the patient. 
For patient-defined targets and outcomes 
of therapies, idiographic measures are ob-
viously more relevant.
The oldest of these approaches is prob-
ably the Target Complaints54. In this ap-
proach, the patient describes three target 
complaints in a clinical interview, and for 
each of these complaints both the thera-
pist and the patient rate how significant 
the problem is. After the treatment, both 
the patient and the therapist are asked to 
indicate on a five-point scale how much 
each of these problems has improved.
Other patient-generated outcome mea-
sures include the Psychological Outcome 
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Profiles (PSYCHLOPS)56, the Simplified 
Personal Questionnaire57, and – in the field 
of child and adolescent mental health – the 
Youth Top Problems58. These instruments 
differ in terms of questions, possible an-
swers and the point in time when they are 
rated. But the general idea is very much 
comparable with the Target Complaints, 
in the sense that the patient indicates 
which problems are important, to what 
extent he/she is affected by them, and the 
improvement during treatment. These 
measures differ from each other in terms 
of reliability and validity55, but all have 
been found to be useful as a clinical tool.
The evaluation of these patient-de-
fined targets and outcomes can be help-
ful in clinical practice in several ways59, 
such as better specifying problems iden-
tified by standardized measures, focus-
ing the attention of the therapist on these 
issues, and increasing patients’ influence 
in the shaping of the agenda of therapy.
There is also some qualitative research 
examining the personal targets and out-
comes of psychotherapies, although most 
of this research has been conducted in 
small and selective samples46. The studies 
included patients receiving different types 
of therapy, and do not point at clear, con-
sistent types of targets and outcomes that 
can apply across patients. Much of this 
research suggests that what patients find 
important in therapy depends on what 
they need at that stage in their lives59.
One study in a small group of patients 
used in-depth qualitative interviews14, 
and found four categories of outcomes 
which were most important for patients: 
a) establishing new ways of relating to 
others; b) reduction in symptoms or 
change in patterns of behavior that used 
to bring suffering; c) better self-under-
standing and insight; and d) accepting 
and valuing oneself.
Another, more recent study was aimed 
at integrating the results of qualitative re-
search on helpful impacts of psychother-
apies60,61. Several categories of helpful 
impacts were identified, including aware-
ness, insight and self-understanding, 
behavioral change and solution of prob-
lems, empowerment, relief, and better 
understanding of feelings.
QUALITY OF LIFE AND RELATED 
TARGETS AND OUTCOMES
There is a growing consensus that tri-
als of psychotherapies and other treat-
ments of mental disorders should not 
only focus on symptoms of disorders 
as targets and outcomes, but also con-
sider the broader concept of quality of 
life62. What quality of life exactly means, 
however, is not so clear. It can be seen as 
a multidimensional construct encom-
passing physical, psychological and so-
cial dimensions of health63. It comprises 
a range of life domains, including social 
relationships, physical abilities, mental 
health functioning, role functioning and 
engagement in daily activities64.
In most outcome studies of psycho-
therapies, quality of life is measured by 
self-report instruments. There is a consid-
erable body of research on the effects of 
psychotherapies on self-reported quality 
of life for most mental disorders. The re-
sults of some of the most important me-
ta-analyses are summarized in Table 3. 
Significant effects of psychotherapies on 
quality of life were found for depression, 
eating disorders and anxiety disorders, 
compared to control conditions. No sig-
nificant effects were found for schizo phre-
nia.
Quality of life also encompasses more 
concrete areas such as income level, em-
ployment and housing status. Many in-
terventions are available for patients with 
mental disorders that are aimed, for ex-
ample, at helping them to get employ-
ment,  or supporting them with hous-
ing69,70. These interventions are, however, 
outside the scope of psychotherapy.
There is some research examining the 
effects of psychotherapies on broader ar-
eas of quality of life. For example, some 
meta-analyses found that psychothera-
pies for depression not only have a sig-
nificant effect on depressive symptoms, 
but also on social support (g=0.38; 95% 
CI: 0.29-0.48)71 and social functioning 
(g=0.46, 95% CI: 0.32-0.60)72. There are 
also indications from a small meta-anal-
ysis that psychotherapy for depressed 
mothers may result in improved parental 
functioning (g=0.67; 95% CI: 0.30-1.04), 
improved mother-child interactions 
(g=0.35; 95% CI: 0.17-0.52) and improved 
mental health of children (g=0.40; 95% 
CI: 0.22–0.59)73. In these meta-analyses, 
a strong association was usually found 
between the effects on psychopathology 
and on aspects of quality of life.
INTERMEDIATE OUTCOMES: 
MEDIATORS AND WORKING 
MECHANISMS
Although most research on psycho-
therapies has focused on symptoms of dis-
orders as outcome, psychotherapists from 
Table 3 Meta-analyses of  randomized trials examining the effects of  psychotherapies compared to control conditions on quality of  life
Study Disorder Type of therapy Comparator N studies SMD 95% CI I2
Linardon & Brennan65 Eating disorders CBT Any control 13 0.39 0.20-0.57 56
Laws et al66 Schizophrenia CBT Any control 10 0.04 –0.12 to 0.19 0
Hofmann et al67 Anxiety disorders CBT Any control 21 0.56 0.32-0.80 NA
Kolovos et al64 Depression Any psychotherapy Any control 31 0.33 0.24-0.42 21
Kamenov et al68 Depression Psychotherapy Pharmacotherapy 8 0.05 –0.19 to 0.29 NA
Psychotherapy Psychotherapy + pharmacotherapy 6 –0.36 –0.62 to –0.11 NA
CBT – cognitive behavior therapy, SMD – standardized mean difference, NA – not available
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different schools have very diverse views 
on how these improvements are realized. 
Each type of therapy has its own theoreti-
cal model on how change is brought about 
in a patient. From a research perspective, 
CBT is dominating the field, with by far 
the majority of randomized trials focusing 
on this type of therapy.
CBT is focused on changing biases in 
thinking that are postulated to cause psy-
chopathology, and CBT therapists assume 
that, when they succeed in changing these 
biases, the therapy is successful and the 
symptoms are taken away.
The evidence supporting the change 
in these biases as a mediator of CBT is, 
however, not very strong. Most research 
in this area has been conducted in depres-
sion. A meta-analysis of 26 randomized 
trials of CBT for depression found that dys- 
functional thinking did indeed change 
as a result of that therapy74. However, it 
also changed with other therapies, that 
are not specifically aimed at dysfunction-
al thinking, and there was no clear dif-
ference between CBT and these other 
ther apies. It is therefore possible that 
dysfunctional thinking can better be seen 
as a manifestation of depression, that im-
proves when depression improves, and 
not as a mediator or core part of the work-
ing mechanism of CBT. As such, there is no 
evidence that changing biases in thinking 
should indeed be regarded as a target or 
outcome of an individual psychother apy.
One important category of psychother-
apies, the psychodynamic ones, assume 
that psychopathology is related to the 
quality of the person’s early attachment 
relationships75, and to significant child-
hood experiences that may have been 
accompanied by frustration, shame, loss, 
helplessness, loneliness, or guilt76. These 
experiences during developmental stag-
es shape the personality and generate 
the vulnerability to psychopathology lat-
er in life. Symptoms of mental disorders 
are not seen as the core of the problem, 
but as a consequence of the broader per-
sonality problems. Therapies are there-
fore not aimed at symptoms but at solving 
the deeper intrapersonal problems. They 
are assumed to work via the reduction of 
unconscious conflicts77.
There is some discussion about wheth-
er or not unconscious problems can be 
measured empirically77,78. Although there 
is no reason why they could not be exam-
ined as a mechanism of change of psycho-
dynamic therapies, hardly any research on 
these mediators or mechanisms of change 
is available.
A third theoretical model for how psy-
chotherapies work is the “common fac-
tors” one53,79-81. In this model, psychother-
apies are assumed not to work through the 
specific techniques that are employed, but 
through factors that are common across 
all types of therapies. The relationship 
between patient and therapist is an im-
portant common factor, but also the hope 
and expectations that the problems will be 
solved (through the rationale given by the 
therapist on what the causes of the prob-
lems are and how they can be solved). So, 
according to this model, the development 
of an effective relationship with the pa-
tient is a necessary target of the therapy.
The main problem with intermediate 
targets and goals of psychotherapies is that 
randomized trials can show that a therapy 
works, but it is much more complicated to 
show how a therapy works81-83. Research 
on working mechanisms and mediators 
to date is always correlational: in order to 
establish that a mediator is indeed a causal 
factor in the recovery process, studies not 
only have to show that the outcome as well 
as the mediator improves, but also that 
these improvements are associated with 
each other. In addition to that, a temporal 
relationship has to be shown (change in 
the mediator comes before change in the 
outcome), a dose-response association 
has to be documented (stronger change 
in the mediator is associated with strong-
er change in the outcome), and evidence 
has to be provided that no third variable 
causes change in both the mediator and 
the outcome. And even if this is all demon-
strated, supportive experimental research 
and a strong theoretical framework are 
needed to make a convincing case that a 
variable may indeed be a true mediator.
Currently, no (common or specific) fac-
tor meets these criteria and can thus be 
considered an empirically validated work-
ing mechanism. As Kazdin83 argues, “after 
decades of psychotherapy research, we 
cannot provide an evidence-based expla-
nation for how or why even our most well 
studied interventions produce change”. 
This means that psychotherapies can have 
intermediate targets and outcomes, but 
there is no evidence that these targets and 
outcomes do indeed have an impact on 
mental health problems.
NEGATIVE OUTCOMES
“First do no harm” is an important in-
junction in all biomedical interventions84. 
Negative effects are a specific type of tar-
gets and outcomes, in the sense that they 
should be avoided instead of realized. Al-
though the importance of negative effects 
of psychotherapies has been described 
for several decades85,86, only recently this 
is emerging as one of the core issues to 
be prioritized in research87-90. At the mo-
ment, it can be said that there is a consen-
sus in the field of psychotherapy research 
that negative effects should be better ex-
amined and that they have mostly been 
neglected in much of this research up to 
now89,91.
It is not clear how negative outcomes 
of psychotherapies should be defined91,92. 
Important types of negative outcomes in-
clude an increased risk of deterioration 
during therapy90 and serious adverse e-
vents93. However, there are many other 
types of negative outcomes that could be 
considered94. For example, non-response 
and drop-out can also be considered as 
negative outcomes.
There are several examples of so-called 
“fringe” or potentially harmful therapies, 
such as rebirthing, scared straight inter-
ventions, critical incidence stress debrief-
ing, and recovered-memory techniques87,95. 
Such therapies are assumed to have over-
all negative effects, and should be avoided 
altogether. However, negative effects can 
also occur in evidence-based psychother-
apies. Although the mean level of symp-
toms may improve with these therapies 
more than with control interventions, this 
does not mean that in some individuals 
the therapy cannot have negative effects.
Systematic research into negative ef-
fects of psychotherapies is mostly fairly 
recent. A conventional meta-analysis of 
controlled trials of psychotherapies for 
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depression found that only 6% of all trials 
reported deterioration rates90. The pooled 
risk ratio (RR) of deterioration in the 18 
studies (23 comparisons) that did report 
these rates was 0.39 (95% CI: 0.27-0.57), 
meaning that patients in the psycho-
therapy groups had a 61% lower chance 
to deteriorate than patients in the control 
groups. Most studies defined deteriora-
tion according to the criteria proposed 
by Jacobson and Truax96, which indicate 
that the patient’s levels of psychopathol-
ogy have become considerably worse and 
meet criteria for a severe disorder.
Individual patient data (IPD) meta-
analyses are better suited to examine de-
terioration rates in psychotherapy trials. 
Randomized trials typically do not have 
sufficient statistical power to detect dif-
ferences in deterioration rates between 
different conditions, because these rates 
are usually low. In IPD meta-analyses, the 
primary data from individual trials are 
collected and merged into one dataset. 
Because the resulting datasets are usu-
ally large, they have sufficient statistical 
power to examine relatively rare events, 
such as deterioration.
In one IPD meta-analysis, 16 trials with 
1,700 depressed patients comparing CBT 
with antidepressant medication were in-
cluded97. Five to 7% of patients showed 
any deterioration (an increased score 
on the HAMD or BDI of one point), 1% 
showed reliable deterioration (increase of 
more than 8 points on the HAMD, or more 
than 9 points on the BDI), and 4 to 5% 
showed extreme non-response (a post-
treatment HAMD score of 21 or higher, or 
a BDI score of more than 31). No signifi-
cant difference between CBT and antide-
pressant medication was found on any of 
these rates.
In two other IPD meta-analyses, dete-
rioration rates in Internet-based guided 
self-help CBT for depression were exam-
ined. In one of them, data from 18 trials 
with 2,079 participants were included98. 
The rate of reliable deterioration was 3% 
in CBT and 8% in the control conditions 
(RR=0.47; 95% CI: 0.29-0.75). In the oth-
er meta-analysis, focusing on Internet-
based CBT without any human support, 
13 trials with 3,805 participants were in-
cluded, and it was found that 6% in the 
CBT conditions deteriorated, compared 
to 9% in the control conditions (odds ra-
tio, OR=0.62; 95% CI: 0.46-0.83)99.
ECONOMIC OUTCOMES
In economic studies, the outcomes of 
therapies are often measured through 
cost-utility analyses (CUAs) or cost-ef-
fectiveness analyses (CEAs)100.
For most mental disorders, no more 
than one or two CEAs or CUAs of psycho-
therapies are available. This is the case for 
bipolar disorder101, obsessive-compul-
sive disorder102, social anxiety disorder, 
panic disorder, post-traumatic stress dis-
order100,103, and generalized anxiety dis-
order100,104. For depression, more studies 
are available105. However, most of these 
studies focus on CBT, while for other ther-
apies there is hardly any research. Avail-
able evidence does suggest that CBT for 
depression is cost-effective compared to 
pharmacotherapy in the long term105.
A growing number of CEAs and CUAs 
have focused on Internet-delivered inter-
ventions, with some evidence that they 
are more cost-effective as compared to 
waiting list, care-as-usual, group cogni-
tive behavior therapy, attention control, 
or telephone counseling106, although this 




In this paper we described the main 
types of targets and outcomes of psycho-
therapies. But, what is the most important 
target or outcome? That depends very much 
on whom you ask this question. Most out-
come research is focused on symptoms of 
a mental disorder. However, as we noticed, 
patients may not consider symptom re-
duction as the only or the most important 
outcome. Therapists also have their own 
perspectives on the targets and outcomes 
of therapies. They typically work in health 
systems where they are assumed to treat 
the mental disorder of the patient. So, one 
of their main targets is to reduce the symp-
toms of the disorder. But they also want to 
help the patient to solve his/her personal 
problems. Furthermore, they usually work 
within a theoretical framework, such as the 
cognitive-behavioral, the psychodynamic 
or the “common factor” model, each of 
which has important intermediate targets.
But there are further stakeholders. 
Health insurance companies also have 
their own views on what the targets and 
outcomes of therapies should be. They 
want the therapy to be effective, but to 
the lowest economic costs. Societies at 
large want therapies to help individual 
patients, but they also expect them to re-
duce the societal burden of mental disor-
ders, in terms of economic costs, but also 
of problems caused in the public domain, 
for example by patients with an antiso-
cial personality disorder. Relatives want 
the best outcomes for patients, but often 
also have their own targets and outcomes. 
Employers are particularly interested in 
getting patients with mental disorders 
back to work and as productive as they 
were before they developed the disorder.
So, the question of what is the most 
important target and outcome of a psy-
chotherapy is very much dependent on the 
stakeholder considered. Currently, most 
research is focused on symptomatology 
of mental disorders, but it could easily be 
argued that patients should have a strong-
er voice in deciding what the most impor-
tant outcomes are. Patients are the ones 
who suffer from mental disorders and, as 
long as we do not exactly know what these 
disorders are or what their causes may 
be, we should rely on the ones who suf-
fer from them to decide what outcomes 
should have the priority.
CONCLUSIONS
It is not yet clear what mental disor-
ders are and what are the causal pathways 
that lead to them. That makes it difficult to 
decide what the targets and outcomes of 
psychotherapies should be. In this paper, 
the different perspectives on this issue and 
the different types of outcomes were de-
scribed.
The DSM and ICD systems have dom-
inated the research field in the past dec-
ades and have led to a strong focus on core 
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symptoms of mental disorders as the main 
outcome of therapies. However, there is 
growing criticism of the DSM/ICD systems 
and, in line with this, the ques tion is increas-
ingly raised whether symptoms should be 
the core outcome of therapies. This paper 
highlighted that pa tients often have differ-
ent perspectives concerning targets and 
outcomes of psy chotherapies. Quality of 
life is one of the broader types of out comes 
being examin ed in randomized trials. 
Therapists have other intermediate targets, 
and that depends heavily on the type of 
therapy they are implementing, while there 
is very little evidence that these intermedi-
ate goals are associated with outcomes. 
Economic outcomes are also important for 
patients, health care providers, and socie-
ties. Patients should ultimately have the 
strongest voice in deciding what targets 
and outcomes of psychotherapies should 
have priority.
It is also important that a consensus in 
the research field is achieved on what the 
core outcomes of randomized trials of psy-
chotherapies should be. Because of this 
lack of consensus, many different outcomes 
and instruments are used across trials. Even 
if the instruments measure the same con-
structs, their heterogeneity may cause in-
consistencies in reporting and difficulties 
in comparing and combining the find-
ings in systematic reviews and meta-anal-
yses108-110. Furthermore, the quality of out-
come measures varies widely, and in many 
cases the most reliable and valid outcome 
measures are not selected108. Standard-
ization of the selection of outcomes and 
their measures is therefore very much 
need ed.
Several important types of outcomes 
have not been examined sufficiently in 
psychotherapy research, including out-
comes from the patients’ perspective, neg-
ative outcomes, mediators and intermedi-
ate targets and outcomes, as well as eco-
nomic outcomes. It is important that more 
research is conducted on these outcomes.
The question of what the targets and 
outcomes of psychotherapies should be 
is not easy to answer and depends on 
which perspective one takes. Because of 
the huge burden of mental disorders, this 
is, however, an essential question, and an-
swering it should be one of the priorities 
in the next decade.
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